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Influenza virus infections are responsible for more than 250,000 deaths annually. Influenza
virus isolation, propagation, and characterization protocols are critical for completing
reproducible basic research studies and for generating vaccine seed stocks. Detailed
protocols for the isolation and identification of influenza virus have been recently reported
(Eisfeld et al., 2014). However, there are few standardized protocols focused on the
propagation and characterization of viral isolates, and as a result, viruses propagated
in different conditions in different laboratories often have distinct in vitro and in vivo
characteristics. Here, we focus on influenza A virus propagation and characterization
in the laboratory taking into consideration the overall quality and composition of the virus
stock to achieve consistency in virus yield, virulence, and immunostimulatory activity.
Keywords: influenza, defective viral genomes, defective interfering particles, hemagglutinin mutations, virus
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INTRODUCTION
Background
Influenza virus is a respiratory pathogen that can cause severe disease and even death in some
individuals. According to the Centers for Disease Control and Prevention, influenza virus infects
about 5–20% of the US population every year with more than 200,000 patients hospitalized.
Different strains of influenza virus circulate among the population and variations of these strains
arise regularly due to the high rate of mutations introduced by the viral polymerase (Salter et al.,
2011; Eshaghi et al., 2014). In addition, new strains are sporadically generated due to re-assortment
of the influenza virus genomic segments (Nelson et al., 2008; Danzy et al., 2014). This variability
allows the virus to escape from the host immune response, permits multiple infections during
the host lifespan, and promotes the generation of novel viruses that spread rapidly through the
population.
Because of the significant impact of influenza virus in public health, multiple research groups
around the globe are invested in researching influenza virus biology and pathogenesis. In addition,
the influenza vaccine is adjusted annually to match the circulating virus strains and better protect
the population. These efforts require frequent preparation of the virus in small (in the case of
research laboratories) and large (in the case of vaccine manufacturers) scales. Lack of consistency
in the methods utilized for influenza virus propagation and their characterization results in
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discrepancies in the yield, pathogenesis, and immunostimulatory
properties of presumably identical strains of the virus (Marriott
and Dimmock, 2010).
Two major influenza viruses circulate among the human
population: influenza A virus (IAV) and influenza B virus (IBV).
Since IAV is more broadly used in research laboratories, we
will focus this article on IAV, however, similar principles and
procedures apply to IBV. Based on our experience with IAV
H1N1 and H3N2 subtypes, it is likely that this protocol applies
to many influenza virus subtypes.
Existing Methods
IAV can be grown in 9–11 day old embryonated chicken
eggs or in tissue culture in permissive cells, usually Madin-
Darby Canine Kidney (MDCK) cells (Liu et al., 2009; Hussain
et al., 2010) or kidney epithelium Vero cells, in the presence
of trypsin (Tobita et al., 1975; Kaverin and Webster, 1995;
Govorkova et al., 1999). Embryonated eggs or cells in culture
are inoculated with a 10−2–10−4 dilution of a virus stock
that could be originated from “seed virus” (i.e., a previous
stock of virus propagated in the laboratory), a commercial
source, or infected tissue (mouse lungs for mouse-adapted
viruses or human respiratory secretions for human viruses).
The virus is grown at 37◦C for 40–72 h (sometimes longer)
prior to collection of allantoic fluid or cell supernatants for
storage and characterization. Embryonated chicken eggs have
the advantage of producing high virus titers in a shorter period
of time and these viral preparations are free of mammalian
pathogens. Although there are safe well-characterized cell lines
that are approved for generating influenza vaccines in some
countries (Donis et al., 2014; Soema et al., 2015), low levels
of contamination with mycoplasma or mammalian viruses are
common in cell lines normally used to propagate influenza
viruses for laboratory studies and their use is discouraged (David
et al., 2010).
After growth, characterization of the virus stock is usually
limited to determining the virus titer. Many laboratories estimate
total viral particles in each preparation based on the amount of
hemagglutinating units by calculating the end point dilution for
hemagglutination of chicken, turkey, or guinea pig red blood
cells (Killian, 2014). A caveat of this approach is that it does not
distinguish infectious from non-infectious particles or fragments
of viral or cell proteins containing the viral hemagglutinin
protein. Titers of infectious units are usually calculated by
counting viral plaque forming units (PFU) after infecting MDCK
cells with different dilutions of virus, or by estimating the
50% tissue culture infectious dose (TCID50) (Szretter et al.,
2006). Viruses prepared for vaccine purposes undergo additional
more rigorous quality control processes to confirm the antigenic
properties of the virus and, in particular, the antigenic quality
of the surface HA and NA proteins (Wood and Robertson,
2004).
The Problem
Most research groups do not take in consideration variations
in the composition of the viral isolates that are used to create
influenza preparations and/or the modifications introduced to
the virus during imprecise propagation conditions (Robertson
et al., 1993; Marriott and Dimmock, 2010). Virus replication
generates multiple products in addition to full-length standard
viruses. A major byproduct is a set of severely truncated viral
genomes collectively named defective viral genomes (DVGs) for
their inability to replicate without a standard virus (VonMagnus,
1954; Lazzarini et al., 1981; Perrault, 1981; Lopez, 2014). IAV
DVGs were first described by von Magnus in the late 1940s after
growing viruses at high multiplicities of infection (MOI) (Von
Magnus, 1951). IAV DVGs contain at least one deletion in one
of the virus genomic segments (Hutchinson et al., 2010; Scott
et al., 2011) and IAV DVGs with different activities have been
described (Brooke, 2014). Although no consensus exists whether
deletions in specific viral segments confer specific properties
to the virus, IAV DVGs with the ability to interfere with the
replication of the standard virus have been mostly observed
as deletions in the genomic segments encoding the polymerase
genes (PA, PB1, and PB2) (Noble and Dimmock, 1995). Deletions
in the genomic segment that encodes for the NS1 protein, which
strongly antagonizes the host antiviral response (Ngunjiri et al.,
2013), leads to the production of viruses able to induce high
levels of type I interferon (IFN) (Ngunjiri et al., 2012). Because
of their interference activities, DVGs are also called defective
interfering particles (DIPs). IAV DVGs have been found in viral
stocks generated during growth in both embryonated eggs or
in cell culture. DVGs are generated under a wide range of
conditions that include high MOI and extended growth periods
(Von Magnus, 1951; Magnus, 1954; Janda et al., 1979). Data
obtained in our laboratory illustrating the impact of growing
conditions in the accumulation of DVGs in virus stocks is shown
in Figure 1. Remarkably, we also found that live-attenuated IAV
vaccine stocks of recent years contain DVGs (Figure 2).
A large body of evidence demonstrates that infection of mice
with IAV preparations with a high content of DVGs protects
from pathology and diminishes viral load (Noble and Dimmock,
1995; Dimmock et al., 2008; Saira et al., 2013; Tapia et al., 2013;
Boergeling et al., 2015). The protection conferred by IAV DVGs
is largely mediated by type I IFNs demonstrating an enhanced
immunostimulatory activity for virus stocks containing high
levels of DVGs (Janda and Nayak, 1979; Frensing et al., 2014).
Examples of the impact of DVGs in the antiviral response are
shown in Figure 3.
Minor viral mutations generated during virus expansion
include the acquisition of HA mutations that facilitate efficient
replication in eggs and cell cultures. Many of these mutations
affect the antigenic properties of the virus (Katz and Webster,
1989; Robertson et al., 1993; Rocha et al., 1993). In addition,
a vaccine mismatch that occurred in the 2012–2013 influenza
season resulted almost exclusively from an HA mutation that
emerged when the H3N2 vaccine strain was propagated in
chicken eggs (Skowronski et al., 2014).
Standardizing the procedures to prepare, propagate,
and characterize virus stocks focusing on maintaining the
quality of the virus in regards of their composition, yield,
pathogenesis and immunostimulatory properties is essential
for reproducible research and consistent preparation of vaccine
stocks.
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FIGURE 1 | DVGs accumulate in viral stocks when expanded at high
multiplicity of infection (MOI) or extended periods of time. As examples
to illustrate the accumulation of DVGs in virus stocks propagated in different
conditions (A) shows viral PCR products amplified from A549 cells infected
with a MOI of 2, 0.2, or 0.02 of IAV HK/x31 (X31) (H3N2) for 6 h. (B) Shows
viral PCR products amplified from A549 cells infected with a MOI 0.1 of
A/California/7/2009 (CA) (H1N1) for 2, 6, 12, 24, or 48 h. Position of base pair
size reference markers is indicated in each gel. Asterisks indicate DVGs
confirmed by sequencing.
OVERVIEW OF THE PROCEDURE
A detailed procedure for the isolation and identification of
IAV was recently reported (Eisfeld et al., 2014). The protocol
described here focuses on the standardization of the conditions
for virus propagation in the laboratory and on characterization
of the virus stocks. This protocol provides quality control
procedures to characterize the DVG content of viral stocks and
includes a strategy to prepare human IAV isolates that can grow
in eggs with minimal HA mutations. These methods have been
used in previous publications (Tapia et al., 2013; Linderman et al.,
2014). Although this is not a clinical protocol, the procedures
described are applicable for the propagation and characterization
of viruses isolated from clinical samples, as well as for the
preparation of virus stocks to be used in the annual preparation of
the influenza vaccine. This protocol also provides themethods for
DVG detection and identification. It is important to note that the
principles discussed here also apply to the propagation of other
RNA viruses, albeit specific details may vary.
Virus Isolation
According to current regulations influenza virus research should
be conducted in laboratories with at least PC2/BSL2 standards
and virus handled in a class II biological safety cabinet. Working
with highly pathogenic viruses requires higher biosafety levels.
The steps in this protocol are summarized in Figure 4.
Regardless of the virus source, seed virus should be initially
grown from a single virus clone isolated by plaque purification.
FIGURE 2 | IAV DVGs are found in live-attenuated influenza vaccines.
(A) PCR products detecting DVGs in live attenuated influenza vaccine stocks.
Lanes 1, 2, and 3 represent live influenza vaccine NR-17600 intranasal spray
formula for the 2009–2010 season, live influenza vaccine NR-21987 intranasal
spray formula for the 2010-2011 season, and live influenza vaccine NR-36465
intranasal spray formula for the 2011-2012 season, respectively. (B) PCR
products identifying DVGs in A549 cells infected with the different vaccine
stocks. Vaccine isolates were obtained from BEI Bioresources. Position of
base pair size reference markers is indicated in each gel. Asterisks indicate
DVGs confirmed by sequencing.
This approach minimizes contamination of the initial seed virus
with DVGs. Plaques are the result of virus cytopathic effect in the
monolayer and are generated from the expansion of a single virus
particle and the spread of progeny virus to cells immediately next
to the originally infected source. If the initial titer of the seed virus
is unknown, it is recommended to perform serial dilutions of the
virus to obtain isolated plaques. In brief, an 80 to 90% confluent
monolayer of MDCK cells is seeded with a virus inoculum of 10–
50 infectious particles per million cells diluted in the minimum
volume of infection media (IM) necessary to fully cover the cell
monolayer. This inoculum size/cell volume permits isolation of
individual plaques. Cells should test negative for mycoplasma
and other pathogens before use. After virus adsorption, IM is
carefully aspirated from the cells. The infected cell monolayer
should then be washed gently with PBS and overlaid with media
containing agarose and TPCK-trypsin to promote multicycle
replication. The agarose limits virus spreading in the plate. The
overlay media should be maintained at 45–46◦C as the cells
will detach if the temperature is too high or the overlay media
will be solidified before use if the temperature is too low. After
adding the overlay media to the plates at room temperature,
plates should be incubated at 37◦C, 7% CO2 for 72 h (Note:
our laboratory uses 7% CO2 in our tissue culture incubator,
however 5% CO2 is also appropriate). Plaqued virus is then
collected by pinching through the agarose layer with a 1ml sterile
micropipette tip. Each agarose plug is collected in a separate
microcentrifuge tube containing 1ml sterile and ice-cold 0.1%
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FIGURE 3 | IAV isolates with a high content of DVGs induce stronger antiviral responses in infected cells. (A) A549 cells were infected with live, attenuated
influenza vaccines at 2.5 fluorescent focus units (FFU) per cell for 24 h. Expression of IFNB1, IFNL1 (IL29), and IFIT1 (ISG56) was examined by RT-qPCR and is shown
as copy number relative to the housekeeping genes β-actin and GAPDH. The numbers under each histogram bar correspond to one influenza vaccine isolate
(NR-17600, NR-21987, or NR-36465) (*p < 0.05, **p < 0.01 by one-way ANOVA post Bonferroni’s multiple comparisons). (B) A/California/7/2009 viruses with low
DVGs (LD) and high DVGs (HD) content were used to infected A549 cells (MOI = 0.5). Gene expression was analyzed after 24 h (**p < 0.01 by two-tailed t-test). All
error bars indicate mean ± SEM of three independent experiments.
gelatin in PBS. If the plaqued virus will be expanded on the same
day of collection, the virus can be stored at 4◦C. Otherwise, the
plaqued virus stock should be aliquoted and quick-frozen in a dry
ice/ethanol bath and stored at−80◦C.
Preparation of a Seed Virus Stock
Plaqued virus can be expanded to prepare a seed virus
stock by inoculating a fraction of the preparation into plates
seeded with MDCK cells or into embryonated chicken eggs
(details below). Inoculated MDCK cells should be incubated
for 24 h in the presence of TPCK-trypsin. The chicken
eggs allantoic fluid should be harvested 40 h after injection.
Longer incubation times will promote the generation of DVGs.
Supernatants containing seed virus are collected and centrifuged
to remove debris before aliquoting and quick-freezing for storage
at−80◦C.
Seed Virus Characterization and Quality
Control
Before proceeding to expand the seed virus into a working stock,
the virus should be tested for DVGs. An initial estimation of the
presence of defective genomes can be obtained by determining
the ratio between infectious particles and total viral particles
in the preparation. Infectivity titer (I) measures only complete
virus particles able to replicate, while total titer (T) measures all
virus particles even those with incomplete or truncated segments.
As different strains of IAV virus accumulate DVGs at different
rates, this procedure is only useful if the expected ratios are
known. Table 1 shows examples of I/T ratios in different IAV
strains with a low (LD) or high (HD) content of DVGs. Virus
containing DVGs have 3–20 times lower ratios than viruses
lacking DVGs.
Infectivity (I) Titer Measurement
Two methods can be used to determine the amount of infectious
viral particles in the stock: 50% tissue culture infectivity dose
(TCID50) and plaque assay (plaque-forming units; PFU) (Szretter
et al., 2006). In brief, to determine TCID50,1/10 dilutions of
the virus stock are seeded in triplicates or quadruples using the
Reed and Muench method (Reed and Muench, 1938). The virus
is seeded over a monolayer of MDCK cells and incubated in
the presence of TPCK-trypsin for 72 h at 37◦C, 7% CO2 (Note:
our laboratory uses 7% CO2 in our tissue culture incubator,
however 5% CO2 is also appropriate). Cytopathic effect or
the presence of virus in the supernatant (as determined by
hemagglutination assay as described below) is used to determine
end point dilutions. To determine PFU, virus dilutions are
seeded over a monolayer of MDCK cells and incubated in the
presence of overlay media containing agarose and TPCK-trypsin
for 72 h at 37◦C, 7% CO2. After removal of the overlay media
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FIGURE 4 | Summary of the protocol for generation of viruses with a
low DVG content. Details of each procedure can be found in the text.
(agarose), themonolayer is stained with crystal violet and plaques
are counted.
Total (T) Titer Measurement by the
Hemagglutination Assay
Hemagglutination, the ability of the viral HA protein to bind
and agglutinate red blood cells, depends on the amount of HA
protein on the surface of membranes. The hemagglutination titer
is calculated based on the end point dilution of virus able to
agglutinate a set concentration of chicken, turkey, or guinea pig
red blood cells (Szretter et al., 2006).
Detection of DVGs by PCR
IAVDVGs contain at least one truncated genomic segment in the
virus particle. A PCR assay that amplifies all eight influenza virus
TABLE 1 | I/T ratios in different IAV strains with a low (LD) or high (HD)
content of DVGs.
Virus Status Infectivity titer (I):
(log10)TCID50/25
µl
Total titer
(T): HA/25
µl
I/T
A/Puerto Rico/8/1934 LD 8.4 2048 120× 104
A/Puerto Rico/8/1934 HD 7.7 1024 4.9× 104
A/New Caledonia /03/2005 LD 6.4 256 10,000
A/New Caledonia /03/2005 HD 5.9 256 3000
A/California/7/2009 LD 4.7 64 800
A/California/7/2009 HD 4.4 128 200
segments using a universal set of primers, or PCR assays using
specific set of primers for each viral genomic segment, should be
used to determine the presence of DVGs in the virus stock (Zhou
et al., 2009; Frensing et al., 2014). Upon extraction, cloning,
and sequencing of the amplicons, this method also allows the
identification of the specific defective viral genome. The majority
of the IAV DVGs described to date are around 300–700 bp
long. Amplicons of that size should be cloned and sequenced to
confirm the presence of DVGs.
Propagation of Virus Stocks Maintaining a
Low DVG Content
DVG-free seed IAV is propagated in 9–11 day old embryonated
chicken eggs to generate a working virus stock. Each egg
produces an average of 8ml of virus-containing allantoic fluid.
It is essential to carefully follow established virus growth
conditions to avoid the generation of DVGs during propagation.
Egg inoculations with highly concentrated virus or extended
growth periods should be avoided. Details of the process of egg
inoculation were recently described (Szretter et al., 2006; Eisfeld
et al., 2014). To maintain low levels of DVG, eggs are inoculated
using aseptic techniques with no more than 30,000 TCID50 of
the seed virus diluted in 100µl of PBS. Inoculated eggs are
incubated at 37◦C with 45% humidity for 40 h. Allantoic fluid
is then collected after euthanizing the embryo at 4◦C for 3–4 h.
Allantoic fluid should be clear; a reddish color indicates red
blood cell contamination and a cloudy color indicates bacterial
contamination. If the yolk sac is disrupted (yellowish color)
the allantoic fluid should be discarded. Each egg should be
collected in separate sterile tissue culture tubes and the allantoic
fluid should be tested for bacterial contamination by inoculating
trypticase soy agar (TSA) plates with sheep blood. Clean allantoic
fluids harvested from different eggs are then pooled, mixed,
aliquoted, and frozen at −80◦C. Alternatively, IAV can be
propagated in clean, mycoplasma-free MDCK or Vero cells by
inoculating 80 to 90% confluent monolayers of cells with virus at
MOI of 0.1 and incubating for 24 h at 37◦C in a tissue culture
incubator. Virus is collected in the cultures supernatants and
centrifuged to remove debris and aliquoted and frozen at−80◦C.
Virus Stock Storage
Allantoic fluid or infected cells supernatant is snapped frozen
in a dry ice/ethanol bath, aliquoted, and stored at −80◦C. To
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maintain the virus infectivity titer, repeated freezing and thawing
must be avoided. Once thawed, virus stocks are kept on ice or at
4◦C and used the same day.
Working Virus Stock Characterization
Working virus stock should then be titrated and analyzed for
DVG content as described above before use. As discussed,
many influenza virus isolates will acquire adaptive mutations
when propagated in eggs and cell culture. This can especially
be a problem with primary human influenza virus isolates.
Virus genomes should be routinely sequenced to determine
if adaptive mutations arose during propagation. Although
adaptive mutations can arise in any gene segment, mutations
in HA are common egg adaptations. At the very least, the
HA gene of each viral preparation should be sequenced.
PCR followed by standard Sanger sequencing can detect
mutations that are abundant in viral preparations, while
Illumina sequencing is recommended to detect minor adaptive
variants.
Reverse-Engineering Viruses so that They
Can Grow in Eggs and Cell Culture
Some viral isolates cannot be grown in eggs or cell culture
without acquiring adaptive HA mutations. When confronted
with this situation, there are at least two options. The first
option, used by many, is to simply passage the virus in eggs until
high titer viral stocks are obtained. Using this approach, viruses
acquire different adaptive mutations and there is often a mixture
of mutant viruses in these preparations. The second option,
that we routinely use, is to use reverse genetics to introduce
specific mutations that promote viral growth in eggs or cell
culture. A detailed description of the reverse-genetics process
has been previously reported (Neumann et al., 2005; Martinez-
Sobrido and Garcia-Sastre, 2010). Strategically introducing
specific adaptive mutations allows the experimentalist to control
the types of adaptive mutants that will be present in the viral
preparation. For example, the A/California/7/2009 H1N1 strain
is difficult to grow in eggs and cell culture because the HA
of this virus does not bind well to sialic acid receptors on
eggs or MDCK cells (Chen et al., 2010). Most preparations of
this viral strain have different HA mutations, and importantly,
many of these adaptive mutations affect antigenicity. We have
overcome this problem by genetically engineering a single HA
mutation (D225G) that allows the A/California/7/2009 virus to
grow in eggs without further adaptive mutations (Linderman
et al., 2014). The D225G HA mutation is antigenically neutral
so these viral preparations that have this mutation can be used
for accurate antigenic analyses. To illustrate the advantages
of this approach, we grew three viral stocks that possessed
the wild-type A/California/7/2009 HA and three viral stocks
that possessed A/California/7/2009 HA that had the D225G
HA mutation (Figure 5). Standard Sanger sequencing revealed
that stocks of the “wild-type” A/California/7/2009 had different
HA mutations, whereas the stocks engineered to have the
D225G HA mutation did not have any additional detectable
mutations.
FIGURE 5 | Limiting HA mutations in engineered viruses. Three different
stocks of wild-type (WT) A/California/7/2009 H1N1 viruses were grown in
eggs. Three stocks of A/California/7/2009 engineered to possess the D225G
HA mutation were also grown in eggs. We sequenced the HA genes of these
viral preparations by Sanger sequencing. Shown are sequencing results of
nucleotides that encode HA residues 194 and 226. All WT preps possessed
mutations, but mutations were undetectable throughout the entire HA gene
isolated from viruses engineered to have the D225G HA mutation (other than
the desired D225G HA mutation). Mutations are shown in bold and italics.
MATERIALS AND EQUIPMENT
Biosafety
• Class II Biological Safety Cabinets
• Approved BSL-2 or enhanced BSL-2 laboratory facilities
for most mammalian and some avian IAVs. Some highly
pathogenic viruses require higher biosafety levels. Identify the
proper biosafety level based on the IAV subtypes and ensure
that all experiments conform to relevant institutional and
governmental biosafety regulations.
• Personal protective equipment (PPE)
• Biohazard trash bags
• Biohazard sharps containers
• Paper towels
• Autoclave
• Ethanol, 70% (vol/vol)
Reagents
Virus Culture in Eggs
• Embryonated, pathogen-free chicken eggs, 9–11 day old
• Egg sealant (paraffin wax or a melted candle)
• Phosphate buffered saline (PBS) pH7.4 (Life technologies, cat.
no. 10010-023)
• Trypticase soy agar (TSA) plate with 5% sheep blood (Thermo
Scientific, cat. no. R01200)
Frontiers in Microbiology | www.frontiersin.org 6 March 2016 | Volume 7 | Article 326
Xue et al. Protocol for Growing Influenza Virus
Cell Culture
• MDCK cells (ATCC, cat. no. CCL 334)
• A549 cells (ATCC, cat. no. CCL 185)
• Mycoplasma removal agent (MP BioMedical, cat. no.
093050044− 5ml)
• DMEM (Life Tech, cat.no.11995073)
• Trypsin-EDTA, 0.25% (wt/vol) (Gibco, cat. no. 25300054)
• Fetal Bovine Serum (FBS), heat-inactivated (Thermo
Scientific, cat. no. 10082-147); 50ml aliquots should be stored
at−20◦C and thawed before use.
• Gentamicin Reagent Solution (Gibco, cat. no. 15750-060)
• Sodium pyruvate solution (Invitrogen, cat. no. 11360070)
• L-Glutamine (Invitrogen, cat.no. 25030-081)
• Penicillin/Streptomycin (Invitrogen, cat. no. 15140122)
Virus Culture in Cells
• Bovine albumin 35% solution (BSA) (Sigma, cat. no. A7979)
• TPCK–trypsin (chromatographically purified, lyophilized
powder trypsin treated with L-(tosylamido-2-phenyl) ethyl
chloromethyl ketone (TPCK)(Worthington Biochemical, cat.
no. LS004454TRTPCK)
Hemagglutination Assay
• Chicken, turkey, or guinea pig red blood cells 5% (vol/vol)
(Lampire, cat. no. 7241409, 7249409, 7243109).
• PBS solution-10X ultra-pure (Denville, cat. no. CP4390-48)
RNA Extraction and PCR for Viral Genome Detection
• TRIzol (Invitrogen; cat. no. 15596018)
• Chloroform (Sigma, cat. no. C2432)
• Ethanol (Decon, cat. no. 64-17-5)
• Isopropanol (Sigma, cat. no. I9516)
• Methanol (Fisher Scientific, cat. no. A412-4) (Chemicals listed
above should only be opened in a fume hood or similar
safety/exhaust system)
• SuperScript R© III One-Step RT-PCR System with Platinum R©
Taq DNA Polymerase (Invitrogen, cat. no. 12574-026)
• Nuclease-free dH2O (Invitrogen, cat. no. 10977-023)
• Primer sequences for one-step PCR for virus detection:
• MB Tuni-12, ACGCGTGATCAGCAAAAGCAGG;
• MB Tuni-13, ACGCGTGATCAGTAGAAACAAGG (optio-
nal: use primers specific for each IAV genomic segment)
Real-Time RT-PCR
• High-Capacity RNA-to-cDNATM kit (Thermo Scientific, cat.
no. 4387406)
• SYBR Green Master Mix (Life Technologies, cat. no. 4368708)
• Primers:
FLU NP forward, CAGCCTAATCAGACCAAATG;
FLU NP reverse, TACCTGCTTCTCAGTTCAAG;
hβ-actin forward, AGAGCTACGAGCTGCCTGAC;
hβ-actin reverse, CGTGGATGCCACAGGACT;
hGAPDH forward, GCAAATTCCATGGCACCGT;
hGAPDH reverse, TCGCCCCACTTGATTTTGG;
hIFN-b forward, GTCAGAGTGGAAATCCTAAG;
hIFN-b reverse, ACAGCATCTGCTGGTTGAAG;
hIL-29 forward, CGCCTTGGAAGAGTCACTCA;
hIL-29 reverse, GAAGCCTCAGGTCCCAATTC;
hISG56 forward, GGATTCTGTACAATACACTAGAAACCA;
hISG56 reverse, CTTTTGGTTACTTTTCCCCTATCC
Agarose Gel Electrophoresis
• Thermo ScientificTM GeneRulerTM 100 bp Plus DNA Ladder
100 to 3000 bp (Fisher, cat. no. SM0322)
• 6X DNA loading dye (Fisher Scientific, cat. no. R0611)
• UltraPure agarose (Invitrogen, cat. no.16500-500)
• dH2O, autoclaved and stored at room temperature
• Tris-Acetate-EDTA (TAE), 10X (Invitrogen, cat. no.
15558026)
Equipment and consumables
Common Equipment
• Micropipettes (1–1000µl capacity)
• Multichannel pipettes (8 and 12 channels)
• Pipette controller
• Vortex mixer
• Water bath
• Refrigerated microcentrifuge (for 1.5-ml and 2-ml
microtubes)(Eppendorf, cat. no. 5415R or equivalent)
• Refrigerated benchtop centrifuge (for 15-ml and 50-ml conical
tubes) (Eppendorf, cat. no. 5810R or equivalent)
• Freezers and refrigerators:−80◦C,−20◦C, and 4◦C
• Ice machine and ice buckets
Common Consumables
• Sterile glass or plastic bottles (500ml)
• Sterile polypropylene conical 15 and 50ml tubes (BD Falcon,
cat. no. 352070 or equivalent)
• Sterile screw-cap microtubes, 2ml (Sarstedt, cat. no.
15071353)
• Snap-cap microtubes, 1.5ml, autoclaved (Eppendorf, cat. no.
022363204)
• Sterile, aerosol-resistant micropipette tips (1–1000µl
capacity)
• Cotton-plugged, sterile serological pipettes (1–25ml capacity)
• 0.2µm and bottle-top microfilters
Virus Culture in Eggs
• Egg trays
• Egg candling light (OvaView or equivalent)
• Egg incubator (Brinsea, OVA-easy 190)
• Moil point chisel
• Syringes (1ml) with 26G 5/8” needle
• Cotton swabs
• Egg cracker or spoon
• Sterile forceps
• Sterile needle (of 1½)
• Sterile tongue depressor
Virus Culture in Cells
• Tissue culture incubator (37◦C, 5–7% CO2)
• Straight-neck polystyrene tissue culture flasks with vented
caps, 25 and 75 cm2
• Polystyrene tissue culture plates with lids, 6, 12, and 96 well
plate
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• Cell counter
• Cell culture microscope
Hemagglutination Assay
• Microtiter plates, U-bottom, 96 well (Thermo Scientific, cat.
no. 2205)
• Reservoirs (Denville, cat. no. P8826-S)
• Sterile pipette tips of various sizes
Real-Time RT-PCR
• 384 well plate (Greiner Bio-One, VWR cat. no. 82051-470)
• PCR strip tubes, 0.2ml (GeneMate, Bioexpress cat. no.
T-3035-2)
• ViiATM 7 Real-Time PCR System with 384-Well Block
(Applied Biosystems, cat. no. 4453536)
• Real-time RT-PCR analysis software (ViiATM 7 Software)
Agarose Gel Electrophoresis
• Microwave
• Glass Erlenmeyer flask, 500ml
• Agarose gel casting tray
• Electrophoresis chamber
• Power supply
• UV light box
• Imaging system for capturing images of agarose gels
Reagent Setup
• Embryonated chicken eggs (9–11 day old): Before
inoculation use an egg candle to check that the shell is
intact, the egg is fertilized, and the embryo is viable. Mark
with a pencil the edge of the air sac.
• Tissue culture media (TCM): Sterile DMEM 500ml, Sodium
pyruvate 5ml (1mM), L-Glutamine 5.5ml (2mM), heat
inactivated FBS 50ml, Gentamicin 500µl (50ng/ml), filter
through a 0.2µm filter.
• Infection media (IM): Sterile DMEM 500ml,
Penicillin/Streptomycin 5ml, BSA 35% 5ml, Sodium
bicarbonate 5% 12ml, filter through a 0.2µm filter.
• Plaque assay media: For a total volume of 15ml necessary
for one 6-well plate: DMEM 6.5ml, DEAE-Dextran 1% 0.3ml,
MgSO4 1.5% 0.3ml, TPCK-trypsin 0.0075 mg, NaHCO3 7.5%
0.3ml, Gentamicin 15µl, Agarose 1.2% 7.7ml.
• TPCK-trypsin stock solution (2.5mg/ml in DMEM):
Dissolve the TPCK-trypsin in DMEM to a concentration of
2.5mg/ml. Aliquot in 50–200µl aliquots and keep at −20◦C.
Before use, thaw the aliquot on ice. Discard after use.
The working concentration should always be tested after
preparation of a new stock.
• RBCs, 0.5% (vol/vol), for hemagglutination assay: The type
of RBC used depends on the virus subtype. For example, recent
H3N2 clinical isolates do not bind to chicken or turkey RBCs
but do still retain some binding to guinea pig RBCs (Klimov
et al., 2012). RBCs should be washed with cold PBS before use
following procedure below:
a. Transfer 5ml of blood to a 50ml tube for centrifugation.
b. Add 45ml PBS and mix gently.
c. Set the centrifuge acceleration and deceleration rates to 5.
d. Centrifuge 5min at 1200 rpm in an Eppendorf 5810R
refrigerated centrifuge or equivalent.
e. Repeat two or three times until the supernatant is clear.
f. Dilute to 0.5% RBCs in PBS.
• TAE, 1X for agarose gel electrophoresis: Mix 10X TAE with
dH2O at a 1:10 (vol/vol) ratio to the desired volume. 1X TAE
can be stored at room temperature for up to 1 year.
• Agarose gel, 1.5% (wt/vol):Mix 1.5 g of agarose with 10ml of
10 × TAE and dH2O to 100ml in a 500-ml glass Erlenmeyer
flask. Microwave on high for 1–2min or until the agarose is
completely dissolved. Add andmix in 10µl Ethidium Bromide
solution (EB) per 100ml gel. Cool the agarose solution slightly,
pour it into an agarose gel cast at room temperature and allow
the gel to set.
Equipment Setup
• Class II biological safety cabinet (BSC): The BSC should be
airflow–certified and fully decontaminated with 70% ethanol
before use.
• Tissue culture incubators: Set incubators to 37◦C with an
atmosphere of 7% (or 5%) CO2 for cell and virus cultures.
Supply a tray of water to provide humidity.
• Egg incubator: Follow the user’s instructions and set the
temperature to 37◦C and humidity to 45%.
• Centrifuges: Cool all centrifuges to 4◦C before use.
DETAILED PROTOCOL OF THE
PROCEDURES
MDCK Cell Culture
a. Thaw frozen cells in a 37◦C water bath.
b. After thawing, transfer to a 15ml conical tube containing 9ml
of TCM.
c. Centrifuge 5min at 1000 rpm in an Eppendorf 5810R
refrigerated centrifuge or equivalent to remove the DMSO.
d. Resuspend the cell pellet in 1ml of TCM. (This is assuming a
1 × 106 cell inoculum. Adjust volume to achieve a density of
1× 106 cells/ml if necessary).
e. Transfer to 1 well of a 6-well tissue culture plate. Add 10µl of
Mycoplasma removal agent/1× 106 cell/ml.
f. Upon confluency, release the cells by adding 0.5ml of 0.25
% trypsin-EDTA followed by a 3min incubation at 37◦C in
a tissue culture incubator. Suspend the cells with a pipette and
add 1ml of TCM prior to transfer to a T25 tissue culture flask
for expansion. Add another 5ml of TCM.
g. When the cells are confluent 2–3 days later, wash the flask
twice with sterile PBS and repeat the trypsinization procedure.
h. Transfer cells to a T75 tissue culture flask and add 10ml TCM.
The cells will be ready to be used 2 days later.
Virus Isolation
a. One day before virus isolation, seed 5 × 105 MDCK cells /
well in TCM in a 6-well plate.
b. To ensure proper virus isolation, it is best that plaques
are picked from plates containing fewer than 50 plaques.
Frontiers in Microbiology | www.frontiersin.org 8 March 2016 | Volume 7 | Article 326
Xue et al. Protocol for Growing Influenza Virus
If initial viral titer is unknown, is best to prepare 10-fold
serial dilution of the virus in IM from 10−1 to 10−8 for
infection.
c. Aspirate the media from the plates containing the cells.
d. Wash the cells twice with 1ml PBS or serum free media.
e. Add 400µl of virus (or virus dilutions) to each well.
f. Let the virus adsorb to the cells for 1 h at 37◦C in a tissue
culture incubator !Caution rock the plates every 15min to
keep wells from drying out.
g. During virus adsorption, prepare the plaque assay media.
Keep the media at 45–46◦C to prevent agarose solidification
!Caution hot plaque assay media will damage the MDCK
cells.
h. After adsorption, aspirate the supernatants using a 1000µl
pipette. If using virus dilutions, start aspirating from most
diluted well. Be mindful of potential cross-contamination.
i. Wash the cells gently with 1ml PBS.
j. Overlay the cells with 2ml of plaque assay medium. Add
the media carefully. Be mindful of not detaching the cells.
Allow the overlay to solidify before placing the plates in the
incubator.
k. Incubate the plates at 37◦C in a tissue culture incubator for
72 h.
l. Pick isolated plaques using a 1ml sterile micropipette tip to
pinch through the overlay media.
m. Place each plug containing a virus plaque (and agar)
in a separate microcentrifuge tube containing 1ml
0.1% gelatin in PBS. This will be your purified virus
stock.
n. If the plaqued virus will be expanded on the same day,
store the virus at 4◦C and continue with the seed virus
preparation procedure described below. Otherwise, the
plaqued virus stock should be aliquoted in 200µl aliquots
and quick-frozen in a dry ice/ethanol bath and stored
at−80◦C.
Seed Virus Preparation
a. One day before virus isolation, seed 2 × 105 MDCK cells in
1ml TCM per well in 12-well plates.
b. Before seeding the virus, aspirate the media from the 12-well
plates.
c. Wash the cells twice with 1ml PBS.
d. Add 200µl of purified virus stock to each well.
e. Incubate the plates at 37◦C in a tissue culture incubator for 1 h.
Rock the plates every 15min to keep wells from drying out.
f. Add 1ml of IM containing 2µg/ml TPCK-trypsin per well
(make sure to titrate each stock of the TPCK-trypsin to
avoid disruption of the monolayer, adjust the concentration
accordingly) and incubate at 37◦C in a tissue culture incubator
for 24 h.
g. Supernatants should be collected and centrifuged for 5min
at 4◦C at 2000 rpm in an Eppendorf 5415R refrigerated
centrifuge or equivalent to remove debris.
h. Aliquot in 200µl aliquots and quick-freeze in a dry ice/ethanol
bath. Store at−80◦C.
Seed Virus Characterization and Quality
Control:
a. Virus Titration by TCID50 (Infectivity Titer):
i. The day before titration prepare 96 well plates with MDCK
cells. Seed the plate with 2 × 104 cells / well in TCM
(100µl/well of a solution of 2 × 106 cells / 10ml TCM).
One plate will fit four samples in triplicates. Prepare asmany
plates as needed.
ii. The day of the titration the cells should be 80–90%
confluent.
iii. In a separate 96 well plate, prepare 1/10 serial dilutions of
the virus in triplicates in IM. Add 180µl of IM to all wells
in the plate. Add 20µl of virus to each well on the first
row. Prepare triplicates for each sample. Leave three rows
for media alone, and include a positive control with a virus
of known titer. Use a multichannel pipette to mix the virus
with the media in the first row and transfer 20µl to the next
row. Change tips, mix, and transfer 20µl to the next row,
continue until the last row. Make sure to mix the virus well
and change the tips for every dilution. Keep the plate on ice
or at 4◦C.
iv. Discard the media of the plate containing the cells and wash
the monolayer twice with 100µl of PBS. Wash gently to
avoid disrupting the monolayer.
v. Using a 12-channel multichannel pipette transfer 25µl /
well of the virus dilutions to the cells and incubate for
1 h at 37◦C in a tissue culture incubator. !Caution start
transferring virus from the bottom of the plate (higher
dilution) to avoid carrying over virus from lower to higher
dilutions.
vi. Add 175µl of IM containing 2µg/ml TPCK-trypsin per
well (make sure to titrate each stock of the TPCK-
trypsin to avoid disruption of the monolayer, adjust
the concentration accordingly) and incubate for 72 h. Be
careful not to contaminate the media with virus from the
plate.
vii. Calculate the virus titer by determining the end point
dilution that test positive for hemagglutination of RBCs.
To do this, add 25µl of PBS per well to a 96 well U-
bottom plates. Prepare the same number of plates than
the number of infected plates. Transfer 25µl of the
cell supernatants to the hemagglutination plate using a
multichannel pipette. Transfer starting from the highest
dilution. Avoid carry over contamination. Add 50µl of 0.5%
RBCs to each well, mix and incubate for 30min at 4◦C
or RT.
viii. Score the titer by determining the last dilution with positive
hemagglutination. Score the number of positive wells for
that last dilution (number of positives out of three). From
this score calculate the TCID50 / 25µl using the following
formula, where “x” corresponds to the dilution:
“+++” 10X TCID50 = 10
X+0.7/25µl
“++−” 10X TCID50 = 10
X+0.4/25µl
“+−−” 10X TCID50 = 10
X−0.1/25µl
To obtain the TCID50 / ml multiply the calculated titer× 40.
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b. Virus Titration by plaque forming units (PFU) (Infectivity
Titer):
i. One day before infection, seed 5×105 MDCK cells per well
in 6-well plates in TCM. One 6 well plate will be used per
each sample. Prepare as many plates as needed.
ii. Before infection, prepare 10-fold serial dilutions of the virus
in IM.
iii. Aspirate the media from the 6-well plates.
iv. Wash twice with 1ml of sterile PBS.
v. Add 400µl of virus dilution to each well.
vi. Adsorb the virus to the cells for 1 h at 37◦C in a tissue
culture incubator !Caution rock the plates every 15min to
keep wells from drying out.
vii. Prepare plaque assaymedia during the adsorption. Keep the
media at 45–46◦C to prevent agarose solidification !Caution
hot plaque assay media will damage the cells.
viii. After the 1 h adsorption, aspirate the supernatant (from
most diluted well to more concentrated well). Be mindful
not to cross-contaminate dilutions and/or viruses when
aspirating.
ix. Wash each well with 2ml of sterile PBS.
x. Add 2ml of plaque assay media, wait to allow the overlay to
solidify before placing in incubator.
xi. Incubate the plates at 37◦C in a tissue culture incubator for
72 h.
xii. Add stationary liquid (acetic acid:methanol:water = 1:4:5)
2ml per well; incubate the plates at 37◦C in a tissue culture
incubator for about 1 h.
xiii. Use a folded syringe needle to remove the agarose overlay.
xiv. Add crystal violet (1% w/v) 1ml per well and incubate for
2min.
xv. Wash by submersion in a water bath until all excess crystal
violet is gone.
xvi. Count plaques in the dilution producing around 50
visible plaques and calculate PFU using the following
formula in where N is the number of plaques, X is
the dilution counted, and V is the virus volume used
per well:
PFU/ml =
N × 10x
V
c. Hemagglutination Assay (Total titer):
i. Using a multichannel pipette add 25µl of PBS to each well
of a 96-well U-bottom plate. Prepare as many plates as
needed.
ii. Add 25µl of the virus stock /well into the first column of
the plate. Each virus stock should be tested in triplicate.
iii. Perform a two-fold dilution series across the plate by
transferring 25µl between wells, disposing of the final 25µl
from the last well.
iv. Using a multichannel pipette add 50µl of 0.5% chicken
RBCs over all wells, mix and incubate for 30min at 4◦C
or RT.
v. Observe endpoint and record the titer per 25µl of the virus.
Positive samples will agglutinate the RBCs. In negative
samples RBCs will settle at the bottom of the U-bottom
plate forming a tight pellet.
d. Infectivity / Total Particle Ratio Calculation
The ratio between Infectivity titer (I) and Total titer (T) equals
to TCID50 per 25µl (or PFU) / HA per 25µl.
e. Testing for the presence of DVGs by PCR:
i. Extract the RNA from infected cells using TRIzol or other
RNA extraction technique.
ii. Use 1µg of RNA from cells infected with seed virus.
iii. Prepare Master mix for one step-RT-PCR
Reagent Volume µl
2X Reaction Mix (Invitrogen #12574-018) 12.5
MB Tuni 12 (or specific F primer) 0.5
MB Tuni 13 (or specific R primer) 0.5
SS III RT/Platinum Taq mix 1.0
RNA 1µg
dH2O to 25µl total
iv. Run PCR program in a thermocycler:
Step Temperature (◦C) Time
1 42 60min
2 94 2min
3 94 30 s
4 45 30 s
5 68 3min Go to step 3 (5 cycles)
6 94 30 s
7 57 30 s
8 68 40 s Go to step 6 (35 cycles).
9 10 Forever
v. Add 4µl of 6X-loading buffer to each sample.
vi. Load the samples into a 1.5% agarose gel.
vii. If seed virus shows no evidence of DVGs, proceed with
virus expansion.
f. Determining if viral stock has prominent mutations.
i. Extract RNA from viral stock usingQiagenViral RNAKit
or by using other RNA extraction technique.
ii. Create cDNA and PCR amplify gene of interest. HA
should always be sequenced and other viral segments
can also be sequenced depending on intended use of
virus.
iii. Gel purify PCR band and sequence product via
standard Sanger Sequencing. Illumina sequencing can be
completed to identify minor sequence variants.
Virus Propagation
a. Virus amplification in embryonated chicken eggs
i. Incubate the eggs at 37◦C in an egg incubator
immediately upon arrival.
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ii. Work at room temperature one tray of eggs at a time.
Return to 37◦C as soon as finished. The embryos need
to be kept warm to survive.
iii. Heat wax or candle until melted.
iv. Wipe clean the eggs with an isopropyl alcohol pad.
Do not “bath” the eggs in ethanol as the embryo
may die due to ethanol toxicity. Work in an aseptic
manner.
v. Use a lamp to candle the eggs and mark with a
pencil the limit between the air sac and the allantoic
cavity.
vi. Use a moil point chisel to carefully break the eggshell
just enough for a needle to penetrate. Break the shell
approximately 1mm over the limit of the air sac and the
allantoic fluid.
vii. Inoculate the eggs though the hole with 30,000 TCID50
of the virus diluted in 100µl of PBS. Make sure that
the needle is pointing straight down as you want to pass
through the membrane and inoculate the virus in the
allantoic fluid. Use a 26G 5/8′′ needle.
viii. Seal the hole with the wax or the melted candle using
a cotton swab. Put the eggs back at 37◦C in an egg
incubator.
ix. Wait exactly 40 h. Longer times will produce variable
virus stocks due to the generation of defective viruses.
x. Transfer the eggs to 4◦C for 3–4 h to kill the embryo.
xi. Work in aseptic conditions. Crack the shell open at the
air sac using an egg cracker or a spoon. Remove the
loosen shell.
xii. Using a sterile needle (16G 1½) carefully remove the
membrane to expose the allantoic fluid.
xiii. Using a sterile tongue depressor carefully move the
embryo to the side while aspirating the allantoic fluid
with a sterile 10ml pipette. Place the allantoic fluid in a
sterile 15ml conical tube on ice. Allantoic fluid is clear
and should not contain yolk (yellowish color). If the yolk
sac is disrupted the allantoic fluid should be discarded.
A red color indicates RBC contamination and a cloudy
appearance indicates bacterial contamination. Change
tongue depressor and pipette for each egg.
xiv. Spin down the allantoic fluid at 4◦C 5min at 2000 rpm in
an Eppendorf 5810R refrigerated centrifuge or equivalent
to remove debris. A sample of the allantoic fluid should
be inoculated in a TSA plate to test for bacterial
contamination.
xv. Pull the allantoic fluid, mix, and aliquot. Typically,
5–10mL of allantoic fluid can be isolated from each egg.
xvi. Aliquots should be snapped frozen in a dry ice/ethanol
bath and kept at−80◦C.
b. Virus amplification in mammalian cell lines
i. One day before virus isolation, seed 5× 105 MDCK cells
/ well in TCM in a 6-well plate.
ii. On the day of inoculation, remove the TCM andwash the
cells twice with PBS.
iii. Add 400µl DVGs free virus with IM to achieve a MOI=
0.1.
iv. Incubate the plates at 37◦C in a tissue culture incubator
for 1 h. Shake the plates every 15min to keep wells from
drying out.
v. Add 2ml of IM containing 2µg/ml TPCK-trypsin per
well (make sure to titrate each stock of the TPCK-
trypsin to avoid disruption of the monolayer, adjust the
concentration accordingly) and incubate at 37◦C in a
tissue culture incubator for 24 h.
vi. Supernatants should be collected and centrifuged
for 5min at 2000 rpm in an Eppendorf 5810R
refrigerated centrifuge or equivalent at 4◦C to remove
debris.
vii. Aliquot in 200µl aliquots and quick-freeze in a dry
ice/ethanol bath and stored at−80◦C.
IMPORTANT! VIRUS CHARACTERIZATION
AND QUALITY CONTROL SHOULD BE
PERFORMED FOR WORKING VIRUS
STOCKS AS DESCRIBED ABOVE FOR
SEED STOCKS.
DVG Cloning and Sequencing
a. Prepare LB plates with a final concentration of 100µg/ml
ampicillin following standard protocols.
b. Use the gel extraction kit for DNA purification.
c. Ligate the DNA to the pGEM-T-easy vector as described
below at 16◦C overnight.
Reagent Volume µl
2X Rapid Ligation Buffer 5
T4 DNA Ligase 1
DNA insert: pGEM R©-T Easy Vector 4 (molecular weight 3:1)
dH2O To 10µl total
d. Transformation: thaw DH5α competent cells on ice.
e. Gently mix cells with the pipette tip (do NOT pipette
up and down) and aliquot 50µl of cells for each
transformation into 15ml tubes that have been pre-
chilled on ice.
f. Add 5µl ligationmix to the cells andmix gently (doNOT
pipette up and down).
g. Incubate the tubes on ice for 30min.
h. Heat shock at 42◦C for exactly 30 s without shaking.
i. Place tubes on ice for 2min.
j. Add 950µl of LB (make sure this does not contain
antibiotics).
k. Rotate on an orbital shaker at 37◦C for 1 h at 200 rpm.
l. Add X-Gal to the plates before using (final concentration
of 40µg/ml X-gal and 0.1mM IPTG per plate).
m. Allow plates to dry and avoid light.
n. Centrifuge the DH5α cells 90 s at 10,000 rpm in a
microcentrifuge.
o. Remove most LB leaving 100-200µl, resuspend the cells
and add to the plate.
p. Swab the cells on the plate.
Frontiers in Microbiology | www.frontiersin.org 11 March 2016 | Volume 7 | Article 326
Xue et al. Protocol for Growing Influenza Virus
q. Incubate the plate at 37◦C overnight.
r. Number each white colony at the bottom of the plate.
Touch each colony with a pipette tip and transfer to a
labeled PCR tube for a colony screening. Put the plate at
4◦C and perform PCR as described below.
Reagent Volume µl
PCR buffer 2
MB Tuni 12 (or specific F primer) 0.8
MB Tuni 13(or specific R primer) 0.8
SS III RT/Platinum Taq mix 0.1
MgSO4 0.6
dNTP 0.4
dH2O 15.3 to 20µl total
s. Run PCR program in a thermocycler:
Step Temperature (◦C) Time
1 94 2min
2 94 30 s
3 57 30 s
4 72 1min Go to step 2 (33 cycles)
5 72 10min
6 4 Forever
t. Run the PCR products in an agarose gel and identify
positive colonies.
u. Pick positive colonies from the plate with a pipette tip
and place them in 2ml LB with ampicillin.
v. Shake overnight on an orbital shaker at 37◦C, 200 rpm.
w. Extract plasmid using the Promega PureYield Miniprep
kit or equivalent.
x. Sequence and analyze using the viral genome as
reference.
Immunostimulatory Activity
a. RNA extraction
Extract total RNA from cell lines using TRIzol or equivalent
reagent following manufacturer’s specifications.
b. RT-qPCR
i. Reverse transcribe 1µg of RNA using the high capacity
RNA to cDNA kit from Applied Biosystem or similar
system.
ii. Dilute the cDNA 1:40 and amplify with specific primers in
the presence of SYBR green.
iii. Perform qPCR reactions in triplicate using specific
primers and the Power SYBR R© Green PCR Master
Mixture in a Viia7 Applied Biosystem Lightcycler, or
similar.
iv. Normalize base on levels of β-actin and GAPDH.
APPLICATIONS
The procedures described in this protocol avoid the
accumulation of the DVGs and adaptive HA mutations
during IAV production. Although this is not a clinical protocol,
the procedures described are applicable to the propagation
and characterization of viruses isolated from clinical samples,
as well as for the preparation of virus stocks to be used in
the annual preparation of the influenza vaccine. It needs to
be kept in mind that some countries have strict regulations
in the cell types allowed for vaccine preparation. DVGs and
mutations can severely affect the virus replication rate and
its virulence. This protocol will help reduce the amount
of DVGs that impact the antiviral immune response and
may solve problems with virus propagation, as some viral
stocks fail to grow to high titers because of their high
content of DVGs. Lastly, this protocol may help minimize
vaccine mismatch because of the acquisition of adaptive
mutations during vaccine preparation. It is important to
note that the principles discussed here also apply to the
propagation of other RNA viruses although specific materials
may vary.
ANTICIPATED RESULTS
In previous studies we used IAV strain A/Puerto Rico/8/1934
(PR8) grown following this method to produce stocks with a high
or low content of DVGs. Mice infected with IAV PR8 LD showed
increased mortality compared to mice infected with IAV PR8 HD
and the lungs of mice infected with PR8 HD had higher Ifnb
mRNA expression indicating that the content of DVGs in IAV
stocks affects virulence (Tapia et al., 2013). Here we use A/New
Caledonia /03/2005 as an example and show that this procedure
is effective in generating virus stocks with minimal DVG
contamination. Among all the isolates tested A/New Caledonia
/03/2005 generates the highest amount of DVGs and at the fastest
rate. As shown in Figure 6, the proposed procedure reduces the
number of DVGs in the virus stock to undetectable levels. In data
not shown, we have tested various other H1N1 isolates and the
mouse adapted X31 (H3N2). In all cases this protocol results
in negligible amounts of detectable DVGs at early times post-
infection compared to virus expanded in conditions promoting
DVG accumulation as illustrated in Figures 1 and 2. As shown in
Table 1 the acceptable I/T ratio for different isolates varies largely.
It is suggested to establish the acceptable I/T ratio for each isolate
by performing the quality control procedures described in this
protocol, establish a criterion for acceptable I/T for each isolate,
and report this criterion in all related publications. We anticipate
that influenza A and B stocks of diverse subtypes will show
similar results, albeit the kinetics for reappearance of DVGs may
differ.
LIMITATIONS
RNA viruses are replicated by an error prone polymerase that
introduces mutations at a rate of 10−6 to 10−4 substitutions
per nucleotide per cell infection (Sanjuan et al., 2010; Regoes
et al., 2013). Despite initiating the virus propagation procedure
from a single virus plaque, it is important to keep in
mind that mutations altering virus fitness may still arise and
DVGs may accumulate during the time course of infection.
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FIGURE 6 | Example of the generation of a IAV virus stock free of DVGs. (A) Viral PCR products amplified from A549 cells infected with a MOI 0.1 of a parental
stock of A/New Caledonia /03/2005 at different times post infection. (B) Viral PCR products amplified from MDCK cells infected for 48 h with A/New Caledonia
/03/2005 seed virus prepared after plaque purification at 10−5 dilution (around 300 TCID50 per well in 6-well plate) from the original stock. (C) Viral PCR products
amplified from A549 cells infected with different MOIs of working stocks of A/New Caledonia /03/2005 containing a high load of DVGs (HD) or depleted of DVGs (LD)
following the proposed protocol. Position of base pair size reference markers is indicated in each gel. Asterisks indicate DVGs confirmed by sequencing.
The main goal of this protocol is to establish consistency
in the viral stocks used for experimentation and vaccine
generation. In our experience, virus amplification following
strict conditions consistently results in undetectable levels of
DVGs in the viral stocks and after 4–6 h of infection in cell
culture. Some viral isolates may have a higher propensity to
generate DVGs than others, and this should be taken into
consideration. Growing the virus at a lower temperature (35◦C)
should be tried in this situation. Lower MOIs of infection
and shorter propagation times can also be tested, with the
caveat of obtaining virus stocks with reduced titer. If DVGs
cannot be eliminated following these procedures, the content
of DVGs in the virus stock should be reported in all related
publications. In addition, because of the low MOI required for
the preparation of seed virus without DVGs, the seed virus
stock may not reach high titers. Multiple rounds of propagation
may be needed to achieve higher titers. The content of DVGs
should be checked in each round of propagation to avoid
contamination.
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